foxo4 dri senolytic 2023 2024 ES2 rapidly destroys TP53-FOXO4 foci leading to TP53 mediated Senolytic therapeutics: An emerging treatment

98 g/wk (%) 60 (24.6) 157 (18.6) .041 Current smoker (%) 49 (20.7) 168 (20.4) .936 Cardiovascular disease (%) 45 (18.2) 119 (13.8) .082 Diabetic retinopathy (%) 44 (23.3) 128 (19.6) .265 Systolic BP, mm Hg 130.1 12.6 128.4 12.3 .047 Diastolic BP, mm Hg 78.010.1 76.99.4 .090 Hypertension (%) 179 (72.5) 574 (66.7) .085 Anemia (%) 48 (19.4) 117 (13.6) .022 Neuropathy (%) 67 (28.0) 179 (21.4) .031 Fasting glucose, mg/dL 139.4 36.6 138.7 37.3 .791 Hemoglobin A1c (%) 7.1 0.9 7.2 1.0 .167 HOMA-IR 1.1 0.9 1.2 2.5 .763 Hemoglobin, g/dL 13.6 1.6 13.8 1.7 .053 MCV, fL 90.44.7 91.7 29.9 .504 Total cholesterol, mg/dL 144.5 27.0 146.5 25.7 .285 Triglyceride, mg/dL 138.8 70.8 137.5 70.6 .800 HDL-cholesterol, mg/dL 45.6 10.5 46.0 10.8 .612 LDL-cholesterol, mg/dL 76.4 24.3 77.6 21.9 .466 AST, IU/L 25.4 10.7 28.2 12.7 .001 ALT, IU/L 23.4 13.4 28.2 16.5 2

[DOI] [PubMed] [Google Scholar] Stupnisek M, Franjic S, Drmic D, et al

It is essential for nerve health to have proper flow of nerve growth factor

Bakht, M

(2022) 7:e154722